Novartis | NVS - Actif À Court Terme





Actif À Court Terme Changement Date
AbbVie USD 33.67B 140M 2026-06
Amgen USD 34.96B 3.49B 2026-06
AstraZeneca USD 27.97B 1.65B 2026-06
Bausch Health Companies USD 6.52B 544M 2026-06
Biogen USD 7.31B 1.88B 2026-06
Bristol-Myers Squibb USD 28.58B 1.37B 2026-06
Canopy Growth CAD 529.47M 4.8M 2026-03
Corcept Therapeutics USD 439.68M 13.64M 2026-06
Drreddys Laboratories INR 301.98B 298.66B 2026-03
Eli Lilly USD 64.67B 9.84B 2026-06
Gilead Sciences USD 12.53B 6.11B 2026-06
GlaxoSmithKline GBP 17.56B 202M 2026-06
Glaxosmithkline GBP 17.76B 5.83B 2026-03
J&J USD 59.77B 601M 2026-06
Merck USD 36.68B 1.66B 2026-06
Novartis USD 27.35B 744M 2026-06
Novartis USD 26.61B 3.85B 2026-03
Pacira USD 615.21M 100.25M 2026-06
Perrigo USD 2.45B 260.7M 2026-06
Pfizer USD 41.36B 1.46B 2026-06
Phibro Animal Health USD 935.51M 41.44M 2026-06
Prestige Brands USD 496.81M 65.33M 2026-06
Roche Holding CHF 35.44B 3.29B 2026-06
Sanofi EUR 31.52B 1.36B 2026-06
Sanofi EUR 30.16B 789M 2026-03
Supernus Pharmaceuticals USD 723.5M 8.08M 2026-06
Zoetis USD 6.36B 118M 2026-06